Data Sheet 1_Urolithin A has antiplatelet effects in contrast to its glucuronide, urolithin B, and isourolithin A.docx

For mechanistic studies, an ELISA-based commercial kit was used.</p>Results<p>Urolithin A was a relatively potent antiplatelet drug with an IC₅₀ of 3.7 ± 1.0 µM in arachidonic acid-triggered platelet aggregation. Further experiments demonstrated that it could also block platelet aggregation induced by collagen, platelet-activating factor, thrombin receptor activator peptide, adenosine diphosphate, and even dithiothreitol.

The findings imply that urolithin A had an effect on the thromboxane A₂ pathway and possibly additional platelet-signalling pathway(s). Combination experiments documented that urolithin can improve the antiplatelet effect of acetylsalicylic acid.</p>Conclusion<p>Our observations suggest that urolithin A can be further investigated or used as a template for the development of antiplatelet drug(s). Additional pharmacokinetic, toxicological and efficacy studies are, however, required to confirm and quantify the extent of this effect in vivo.</p>